Breast Cancer Clinical Trial

Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer

Summary

RATIONALE: Biological therapies, such as tumor necrosis factor, may stimulate the immune system in different ways and stop tumor cells from growing. Studying tumor necrosis factor in samples of tumor tissue and healthy tissue from patients with cancer in the laboratory may help doctors learn how tumor necrosis factor works in tumor tissue and healthy tissue.

PURPOSE: This clinical trial is studying tumor necrosis factor in patients undergoing surgery for primary cancer or metastatic cancer .

View Full Description

Full Description

OBJECTIVES:

Primary

Determine the tumor tissue and normal tissue distribution of colloidal gold-bound tumor necrosis factor in patients with primary or metastatic cancer undergoing surgery.

Secondary

Determine, by histological examination of resected tumor tissue, the acute antitumor effects of this treatment in these patients.
Determine the long-term toxicities of this treatment in these patients.
Determine the response to this treatment in these patients.

OUTLINE: This is a cohort study. Patients are stratified according to disease type (colorectal cancer vs hepatocellular cancer vs pancreatic exocrine cancer vs pancreatic endocrine cancer vs breast cancer vs melanoma vs primary adrenal tumors vs renal cell carcinoma).

Patients receive colloidal gold-bound tumor necrosis factor IV over 15-30 seconds 12-78 hours prior to surgery. Patients then undergo standard-care surgery.

Tumor and normal tissues are removed during surgery for analysis of antitumor effects and tissue distribution of colloidal gold-bound tumor necrosis factor by electron microscopy.

After completion of study treatment, patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 1 year.

PROJECTED ACCRUAL: A total of 108 patients will be accrued for this study.

View Eligibility Criteria

Eligibility Criteria

DISEASE CHARACTERISTICS:

Histologically confirmed primary or metastatic malignancy, including any of the following:

Colorectal cancer
Hepatocellular cancer
Pancreatic exocrine cancer
Pancreatic endocrine cancer
Breast cancer
Melanoma
Sarcoma
Primary adrenal tumors
Renal cell carcinoma
Ovarian cancer
Adenocarcinoma of gastrointestinal origin
Peritoneal mesothelioma
Clinical indication for surgical resection

No known brain metastases

Previously treated brain metastases with no evidence of recurrence allowed
Hormone receptor status not specified

PATIENT CHARACTERISTICS:

Male or female
Menopausal status not specified
ECOG performance status 0-2
Life expectancy ≥ 5 months
Absolute neutrophil count ≥ 1,500/mm³
Platelet count ≥ 100,000/mm³
Creatinine ≤ 2.0 mg/dL
Bilirubin ≤ 2.5 mg/dL
ALT and AST ≤ 3 times upper limit of normal (ULN)
Alkaline phosphatase ≤ 3 times ULN
Hemoglobin ≥ 9.0 g/dL
Ejection fraction ≥ 45% by echocardiogram, thallium stress test, or MUGA (for patients with prior cardiovascular disease)
FEV_1 OR DLCO > 30% of predicted (for patients with prior pulmonary disease)
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception

No active bacterial infection

Localized chronic infection (e.g., mild acne, tinea pedis) allowed
No known bleeding disorder

No other serious illness including, but not limited to, any of the following:

Unstable angina
Severe oxygen-dependent chronic obstructive pulmonary disease
End-stage liver disease
No HIV positivity

PRIOR CONCURRENT THERAPY:

Recovered from prior therapy, including cytotoxic drugs, radiotherapy, surgery, or other anticancer modalities
More than 3 weeks since prior biologic therapy or cytotoxic agents (6 weeks for nitrosoureas) and recovered
No concurrent treatment in a protocol for which patient is being evaluated for response
No other concurrent anticancer treatment

Study is for people with:

Breast Cancer

Phase:

Early Phase 1

Estimated Enrollment:

108

Study ID:

NCT00436410

Recruitment Status:

Completed

Sponsor:

National Institutes of Health Clinical Center (CC)

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Early Phase 1

Estimated Enrollment:

108

Study ID:

NCT00436410

Recruitment Status:

Completed

Sponsor:


National Institutes of Health Clinical Center (CC)

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider